FDA Okays Weekly Option in Achondroplasia - Top-Institutions - MDSpire

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Shriners Hospitals for Children
    Shriners Hospitals for Children

    Tampa, FL

    Key Differentiators

    • Pediatric Orthopedics
    • Genetic Skeletal Dysplasias
    • Pediatric Endocrinology

  • #2

    Boston Children's Hospital
    Boston Children's Hospital

    Boston, MA

    Key Differentiators

    • Pediatric Endocrinology
    • Genetics
    • Orthopedics

  • #3

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Genetics
    • Endocrinology
    • Orthopedics

  • #4

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Endocrinology
    • Genetics
    • Orthopedics

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

Insights into epidemiological and clinical burden of bronchiolitis among hospitalized children: a call for preventive interventions

FOXC1 Duplications Linked to Early-Onset Glaucoma

FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.